<DOC>
	<DOCNO>NCT00845832</DOCNO>
	<brief_summary>This 2 part study investigate safety , tolerability efficacy MabT hera combination RoActemra patient active rheumatoid arthritis despite stable dose methotrexate . In Part 1 study , patient randomize receive either MabThera 0.5g iv placebo day 1 15 , follo wed RoActemra one ascending dose 2mg/kg 8mg/kg week 4 , 8 12 ( MabThera arm ) 8mg/kg ( placebo arm ) . In Part 2 , additional pati ents randomize one 2 group receive MabThera 0.5g day 1 15 follow select dose ( Part 1 ) RoActemra week 4 , 8 1 2 , placebo day 1 15 follow RoActemra 8mg/kg week 4,8 12 . All patient eligible receive extension treatment withRoActemra every 4 week . The anticipated time study treatment 12 month , tar get sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Combination Treatment With MabThera ( Rituximab ) RoActemra ( Tocilizumab ) Versus RoActemra Patients With Rheumatoid Arthritis With Incomplete Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , 1865 year age ; rheumatoid arthritis , functional status IIII ; SJC &gt; =4 ( 28 joint count ) TJC &gt; =4 ( 28 joint count ) screen baseline ; RF and/or antiCCP positive ; may fail 1 approved antiTNF agent ( infliximab , etanercept adalimumab ) ; inadequate response methotrexate , dose 7.525mg weekly least 12 week , stable dose past 4 week . rheumatic autoimmune disease rheumatoid arthritis , significant systemic involvement secondary rheumatoid arthritis ; history , current , inflammatory joint disease rheumatoid arthritis ; diagnosis juvenile idiopathic arthritis and/or rheumatoid arthritis age 16 ; significant cardiac pulmonary disease ; previous treatment biologic agent rheumatoid arthritis ( infliximab , etanercept adalimumab ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>